Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020
Abstract Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising initial results of treatment by immune checkpoint in...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-02-01
|
| Series: | eJHaem |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/jha2.629 |
| _version_ | 1797263287073636352 |
|---|---|
| author | Helena Simeunovic Martina Dickenmann Mitja Nabergoj Helen Baldomero Stavroula Masouridi‐Levrat Gayathri Nair Urs Schanz Jacob Passweg Alicia Rovo Yves Chalandon Ekaterina Rebmann |
| author_facet | Helena Simeunovic Martina Dickenmann Mitja Nabergoj Helen Baldomero Stavroula Masouridi‐Levrat Gayathri Nair Urs Schanz Jacob Passweg Alicia Rovo Yves Chalandon Ekaterina Rebmann |
| author_sort | Helena Simeunovic |
| collection | DOAJ |
| description | Abstract Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising initial results of treatment by immune checkpoint inhibitors, most patients will eventually progress. We analyzed 62 adult patients with relapsed or refractory HL (rrHL) treated by allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in one of three University Hospitals of Switzerland (Zurich, Basel, and Geneva) between May 2001 and January 2020. The primary endpoint was overall survival (OS). Secondary endpoints were relapse‐free survival (RFS), non‐relapse mortality (NRM), and relapse incidence, which were assessed in univariate analysis. The median follow‐up was 61 months (interquartile range 59–139). The 2‐ and 5‐year OS was 54% (standard error (SE) ±12) and 50.2% (SE ±13.3), respectively, and the 2‐ and 5‐year RFS was 40.7% (SE ±16.3) and 34.4% (SE ±19.0), respectively. NRM was 23.1% (SE ±2.2) and 27.4% (SE ±2.5) at 2 and 5 years, respectively. The cumulative incidence of relapse was 36.1% (SE ±5.6) at 2 years and 38.2% (SE ±6.6) at 5 years. Our analysis of allo‐HSCT outcomes in the context of rrHL shows encouraging OS and RFS rates, with the mortality rate reaching plateau at 50% at 2 years after allo‐HSCT. This confirms that allo‐HSCT still remains as a potentially curative option for half of patients with rrHL. |
| first_indexed | 2024-03-12T14:07:02Z |
| format | Article |
| id | doaj.art-ca34f888599049ba8011b94a18ef2ad3 |
| institution | Directory Open Access Journal |
| issn | 2688-6146 |
| language | English |
| last_indexed | 2024-04-25T00:10:36Z |
| publishDate | 2023-02-01 |
| publisher | Wiley |
| record_format | Article |
| series | eJHaem |
| spelling | doaj.art-ca34f888599049ba8011b94a18ef2ad32024-03-13T13:30:48ZengWileyeJHaem2688-61462023-02-014126226510.1002/jha2.629Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020Helena Simeunovic0Martina Dickenmann1Mitja Nabergoj2Helen Baldomero3Stavroula Masouridi‐Levrat4Gayathri Nair5Urs Schanz6Jacob Passweg7Alicia Rovo8Yves Chalandon9Ekaterina Rebmann10University Hospital of Bern (Inselspital) Bern SwitzerlandAarau Kantonsspital Aarau SwitzerlandHôpital Riviera‐Chablais Vaud‐Valais, Rennaz SwitzerlandUniveristy Hospital of Basel (USB) Basel SwitzerlandDepartment of Oncology Division of Hematology Geneva University Hospitals (HUG) Geneva SwitzerlandUniversity Hospital of Zurich (USZ) Zurich SwitzerlandUniversity Hospital of Zurich (USZ) Zurich SwitzerlandUniveristy Hospital of Basel (USB) Basel SwitzerlandUniversity Hospital of Bern (Inselspital) Bern SwitzerlandDepartment of Oncology Division of Hematology Geneva University Hospitals (HUG) Geneva SwitzerlandUniversity Hospital of Bern (Inselspital) Bern SwitzerlandAbstract Despite the high cure rate with initial therapy, approximately 10% of Hodgkin lymphoma (HL) patients are refractory to initial treatment, and up to 30% of patients will relapse after achieving initial complete remission. Despite promising initial results of treatment by immune checkpoint inhibitors, most patients will eventually progress. We analyzed 62 adult patients with relapsed or refractory HL (rrHL) treated by allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in one of three University Hospitals of Switzerland (Zurich, Basel, and Geneva) between May 2001 and January 2020. The primary endpoint was overall survival (OS). Secondary endpoints were relapse‐free survival (RFS), non‐relapse mortality (NRM), and relapse incidence, which were assessed in univariate analysis. The median follow‐up was 61 months (interquartile range 59–139). The 2‐ and 5‐year OS was 54% (standard error (SE) ±12) and 50.2% (SE ±13.3), respectively, and the 2‐ and 5‐year RFS was 40.7% (SE ±16.3) and 34.4% (SE ±19.0), respectively. NRM was 23.1% (SE ±2.2) and 27.4% (SE ±2.5) at 2 and 5 years, respectively. The cumulative incidence of relapse was 36.1% (SE ±5.6) at 2 years and 38.2% (SE ±6.6) at 5 years. Our analysis of allo‐HSCT outcomes in the context of rrHL shows encouraging OS and RFS rates, with the mortality rate reaching plateau at 50% at 2 years after allo‐HSCT. This confirms that allo‐HSCT still remains as a potentially curative option for half of patients with rrHL.https://doi.org/10.1002/jha2.629allogeneic stem cell transplantationHodgkin lymphoma |
| spellingShingle | Helena Simeunovic Martina Dickenmann Mitja Nabergoj Helen Baldomero Stavroula Masouridi‐Levrat Gayathri Nair Urs Schanz Jacob Passweg Alicia Rovo Yves Chalandon Ekaterina Rebmann Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020 eJHaem allogeneic stem cell transplantation Hodgkin lymphoma |
| title | Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020 |
| title_full | Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020 |
| title_fullStr | Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020 |
| title_full_unstemmed | Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020 |
| title_short | Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma in Switzerland, 20 years of experience: 2001–2020 |
| title_sort | allogeneic hematopoietic stem cell transplantation in hodgkin lymphoma in switzerland 20 years of experience 2001 2020 |
| topic | allogeneic stem cell transplantation Hodgkin lymphoma |
| url | https://doi.org/10.1002/jha2.629 |
| work_keys_str_mv | AT helenasimeunovic allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT martinadickenmann allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT mitjanabergoj allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT helenbaldomero allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT stavroulamasouridilevrat allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT gayathrinair allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT ursschanz allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT jacobpassweg allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT aliciarovo allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT yveschalandon allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 AT ekaterinarebmann allogeneichematopoieticstemcelltransplantationinhodgkinlymphomainswitzerland20yearsofexperience20012020 |